Research indicates that inhibition of PCSK9 can protect prostate cancer cells from radiation-induced cell damage, suggesting that PCSK9 may be a promising therapeutic target for enhancing radiosensitivity in prostate cancer 100. Here, PCSK9 is linked to prostate carcinoma.